<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02264587</url>
  </required_header>
  <id_info>
    <org_study_id>GAS-IIS-2013-03</org_study_id>
    <nct_id>NCT02264587</nct_id>
  </id_info>
  <brief_title>Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis</brief_title>
  <acronym>MDGP</acronym>
  <official_title>Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liangzhou Wei</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Qingdao University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects and mechanism of mosapride citrate on
      diabetic gastroparesi.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effect of mosapride on DPG by 13 C - octylic acid breath test.

      IF C13- octylic acid be absorbed by mucous membrane of small intestine, octylic acid will be
      oxidated to CO2.Patients eating food containing C13, and then collect their expired gas at
      15, 30,45,60,75,90,105,120,150,180,210,240min, analyse the mass of C13 by mass spectrometer,
      then can calculate the gastric emptying rate.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The improvement of gastric emptying time after taking the medicine</measure>
    <time_frame>2 weeks</time_frame>
    <description>Gastric emptying time will be tested by C13 breath test.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Gastroparesis</condition>
  <arm_group>
    <arm_group_label>mosapride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mosapride 5mg by mouth, 30 minutes before meals, every times one day for 14days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>domperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>domperidone 10mg by mouth, 30 minutes before meals, every times one day for 14days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosapride</intervention_name>
    <description>Mosapride 5mg by mouth ,3 times one day for 1 4days.</description>
    <arm_group_label>mosapride</arm_group_label>
    <other_name>Gasmotin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>domperidone</intervention_name>
    <description>Domperidone 10mg by mouth ,3 times one day for 1 4days.</description>
    <arm_group_label>domperidone</arm_group_label>
    <other_name>Motilium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18≤ age ≤ 75

          2. Patients coincided to, the WHO diagnostic criteria for diabetes in 1999 (namely have
             diabetes symptoms, plasma glucose tendency for 11.1 / L, at any time or fasting plasma
             glucose tendency for 7.0 / L, or oral glucose tolerance test 2 h plasma glucose levels
             tendency for 11.1 / L）

          3. fasting blood-glucose≤7.0mmol/L and 2h postprandial plasma glucose≤10.0mmol/L

          4. Be diagnosed diabetes more than 5 years, blood sugar steady in one month.

          5. have the following symptoms for over 4weeks: early satiety ,postprandial fullness
             ,nausea, vomting,abdominal distension,belching, inappetence, epigastric pain,
             constipation.

          6. Be diagnosed as Delayed Gastric Emptying by C13 breath test.

          7. Signed informed consent.

        Exclusion Criteria:

          1. take gastrointestinal drugs within 2 weeks prior to screening. Or patients with other
             digestive disease.

          2. All patients will be administrated gastroscope in order to exclude stomach or duodenum
             disease, pyloric obstruction. It's normal in Liver, gallbladder, pancreas,spleen,
             nephridium by Ultrasound examination .

          3. Serious ketoacidosis.

          4. History of abdominal operation.

          5. Thyroid hypofunction or hyperthyroidism.

          6. nervous system disease or autoimmune diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Qingdao University</investigator_affiliation>
    <investigator_full_name>Liangzhou Wei</investigator_full_name>
    <investigator_title>Head of departments</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Domperidone</mesh_term>
    <mesh_term>Mosapride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

